Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Italy Fines Apple €98.6 Million Over App Store Dominance 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz 
PARSIPPANY, N.J., Sept. 05, 2017 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that members of its management team are scheduled to present at the 2017 H.C. Wainwright 19th Annual Global Investment Conference at 10:50 AM ET on Monday, September 11, 2017 in New York City.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Susan Mesco (973) 451-4030 [email protected]
